Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Cipla
Express Scripts
Colorcon
US Department of Justice
Deloitte
Covington
McKesson
Argus Health

Generated: April 25, 2018

DrugPatentWatch Database Preview

VESICARE Drug Profile

« Back to Dashboard

Which patents cover Vesicare, and when can generic versions of Vesicare launch?

Vesicare is a drug marketed by Astellas and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in twenty-two countries.

The generic ingredient in VESICARE is solifenacin succinate. There are thirty drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the solifenacin succinate profile page.
Summary for VESICARE
International Patents:32
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 5
Bulk Api Vendors: 78
Clinical Trials: 47
Patent Applications: 1,123
Drug Prices:see details
DailyMed Link:VESICARE at DailyMed
Drug patent expirations by year for VESICARE
Pharmacology for VESICARE
Medical Subject Heading (MeSH) Categories for VESICARE
Synonyms for VESICARE
((8R)-1-azabicyclo(2.2.2)octan-8-yl)(1S)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate
(+)-Solifenacin
(1S)-(3R)-1-Azabicyclo[2.2.2]oct-3-yl 3,4-Dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate Butanedioic Acid
(1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate
(1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate succinate
(1S)-3,4-Dihydro-1-phenyl-2(1H)-isoquinolinecarboxylic Acid (3R)-1-Azabicyclo-[2.2.2]oct-3-yl Ester Succinate Salt
(1S)-3,4-Dihydro-1-phenyl-d5-2(1H)-isoquinolinecarboxylic Acid (3R)-1-Azabicyclo-[2.2.2]oct-3-yl Ester Hydrochloride
(3R)-1-azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate
[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate
[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate hydrochloride
[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; butanedioic acid
[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate;butanedioic acid
[(3R)-quinuclidin-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; succinic acid
[(8R)-1-azabicyclo[2.2.2]octan-8-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate
1-azabicyclo[2.2.2]oct-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate
1-Azabicyclo[2.2.2]octan-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate butanedioic acid
1-Azabicyclo[2.2.2]octan-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate butanedioic acid (Solifenacin?Succinate)
180468-39-7
2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo(2.2.2)oct-3-yl ester, (1S)-, butanedioate (1:1)
2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,1-azabicyclo(2.2.2)oct-3-yl ester, (R-(R*,S*))-
242478-37-1
242478-38-2
4058AH
A819262
A8910SQJ1U
AB0139087
AB01565949_02
AC1L4BM0
AC1L4BM3
AC1L50Q6
AC1Q5VRD
AJ-47452
AK160479
AKOS015896445
AKOS015994745
AKOS030241618
AM84825
AN-15595
API0000838
AX8032830
BC677662
BDBM50344284
BDBM50370682
Butanedioic acid, cmpd. with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1)
Butanedioic acid, compd with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1)
butanedioic acid; (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid [(3R)-1-azabicyclo[2.2.2]octan-3-yl] ester
C23H26N2O2.ClH
CAS-180468-39-7
CHEBI:135530
CHEBI:32151
CHEMBL1200803
CHEMBL1734
CHEMBL2361425
CS-0371
CS-2661
CS-8096
CTK8F0005
CTK8G3169
D01269
D08522
D0L4YD
DB-001095
DB01591
DSSTox_CID_26783
DSSTox_GSID_46783
DSSTox_RID_81901
DTXSID3048289
DTXSID4046783
FBOUYBDGKBSUES-VXKWHMMOSA-N
FT-0657634
FT-0674629
GTPL7483
HY-A0002
HY-A0034
HY-I0230
I06-1893
KKA5DLD701
KS-00000656
KS-00000ZV0
KS-1286
LS-183550
MFCD09952287
MLS006010416
MolPort-003-850-267
MolPort-003-850-268
NCGC00168778-01
Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylatemonosuccinate
RT-015753
RXZMMZZRUPYENV-VROPFNGYSA-N
S0944
s3048
SCHEMBL109333
SCHEMBL188493
SCHEMBL9971260
SMR004701445
Solifenacin
Solifenacin (hydrochloride)
Solifenacin (INN)
Solifenacin (Succinate)
Solifenacin [INN:BAN]
Solifenacin hydrochloride
Solifenacin succinate
Solifenacin succinate (JAN/USAN/INN)
Solifenacin succinate [USAN]
Solifenacin Succinate Salt
Soliten
ST24049293
Tox21_112639
UNII-A8910SQJ1U
UNII-KKA5DLD701
Vesicare (TN)
Vesicare OD
Vesikur
W-5423
YAUBKMSXTZQZEB-VROPFNGYSA-N
YM 67905
YM 905
YM-53705
YM-67905
YM-905
YM67905
ZINC3936683

US Patents and Regulatory Information for VESICARE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas VESICARE solifenacin succinate TABLET;ORAL 021518-001 Nov 19, 2004 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Astellas VESICARE solifenacin succinate TABLET;ORAL 021518-002 Nov 19, 2004 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for VESICARE
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 2009-04-08

Non-Orange Book US Patents for VESICARE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,174,896 Quinuclidine derivatives and medicinal composition thereof ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for VESICARE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB04/029 United Kingdom ➤ Try a Free Trial PRODUCT NAME: SOLIFENACIN AND/OR PHARMACEUTICALLY ACTIVE SALT THEREOF; REGISTERED: NL RVG 29151 20031216; NL RVG 29152 20031216; UK PL 00166/0197 20040816; UK PL 0016/0198 20040816
2004 00037 Denmark ➤ Try a Free Trial
C0032 France ➤ Try a Free Trial PRODUCT NAME: SUCCINATE DE SOLIFENACINE; NAT. REGISTRATION NO/DATE: NL 30 109 20040816; FIRST REGISTRATION: NL - RVG 29 151 20031216
C014/2004 Ireland ➤ Try a Free Trial SPC014/2004: 20050803, EXPIRES: 20181215
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Cantor Fitzgerald
Mallinckrodt
Colorcon
Accenture
Dow
Cipla
Cerilliant
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.